Dosage ; see below
Combinations ; - see below
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Ticlovas | USV | Surgipharm Ltd | 250mg | 20 | Tablet | per tablet | KES 436.00 |
| Ticlopidine More info | |
|---|---|
| Mode Of Action | Platelet-aggregation inhibitor |
| Drug Indication | Prevention of ischaemic events in patients with history of symptomatic ischaemic disease (especially in patients who cannot tolerate aspirin). |
| Precautions | Avoid few days after recent myocardial infarction and 7 days after ischaemic stroke, renal impairment, hepatic impairment, pregnancy, unstable angina, and patients with increased bleeding e.g. surgery. |
| Contra-Indications | Breast-feeding; active bleeding. |
| Side Effects | Minimal at therapeutic doses. Dizziness, abdominal distress, headache and rashes, duodenal ulceration, constipation. |
| Dosage | 50mg BD |
| Pregnancy Category | Category B1 |
| Pregnancy Category Description | Drugs which have been taken by only a small number of pregnant women and women of child-bearing age with no any established rise in the frequency of malformations or other direct or indirect detrimental effects on the foetus having been noted. Studies in animals have not shown evidence of an increased occurrence of foetal damage. |
| Drug Category | DRUGS ACTI NG ON THE CARDIO-VASCULAR SYSTEM |
| Drug Sub-Category | Platelet-aggregation inhibitors
Dosing ; Dosing: Adult Stroke prevention: Oral: 250 mg twice daily Coronary artery stenting (initiate after successful implantation): Oral: 250 mg twice daily (in combination with antiplatelet doses of aspirin) for up to 30 days Unstable angina, non-ST-segment elevation myocardial infarction (UA/NSTEMI) undergoing percutaneous coronary intervention (PCI) in patients unable to receive clopidogrel (unlabeled dosing): Initial: 500 mg loading dose given at least 6 hours prior to PCI, followed by 250 mg twice daily (in combination with aspirin 75-325 mg once daily). Duration of therapy dependent upon type of stent implanted during PCI. Note: Coronary artery stents: Duration of ticlopidine (clopidogrel preferred) in combination with aspirin: According to the ACC/AHA/SCAI guidelines, ideally 12 months following drug-eluting stent (DES) placement in patients not at high risk for bleeding; at a minimum, 1, 3, and 6 months for bare metal (BMS), sirolimus-eluting, and paclitaxel-eluting stents, respectively, for uninterrupted therapy (Smith, 2005). The 2008 Chest guidelines recommend for patients who undergo PCI and receive a BMS (with ongoing ACS) or a DES (with or without ongoing ACS) that ticlopidine (clopidogrel preferred) be continued for at least 12 months. In patients receiving a BMS without ongoing ACS, ticlopidine (or clopidogrel) may be continued for at least 1 month. In patients receiving a DES, therapy with ticlopidine (or clopidogrel) beyond 12 months may be considered in patients without bleeding or tolerability issues (Becker, 2008). Premature interruption of therapy may result in stent thrombosis with subsequent fatal and nonfatal myocardial infarction. Dosing: Geriatric 250 mg twice daily with food; dosage in older patients has not been determined; however, in two large clinical trials, the average age of subjects was 63 and 66 years. A dosage decrease may be necessary if bleeding develops |